Disclosure of payments made to HCPs and HCOs in the UK
Cooperation between pharmaceutical companies, regulators, Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK.
Our payments to HCPs and HCOs
In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website: www.disclosureuk.org.uk
Temporary changes to the publication of 2019 data on Disclosure UK in June 2020
The ABPI is making a temporary change to the way Disclosure UK data is published to minimise any pressure on the NHS during the COVID-19 pandemic. This means that some of the data will not be broken down as normal. This is a temporary change because of the unprecedented situation, and they remain committed to resuming the normal process as soon as the situation allows.
At GSK, we are committed to transparency in payments to healthcare professionals. As per the ABPI’s guidance, and due to the robust nature of our agreements, we can publish our full 2019 data without impacting on NHS time and resources. More information can be found on the UK disclosures page on gsk.com.
Date of preparation: January 2019, UK/COM/0035/15e(5).